CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 120 enrolled
Drug / intervention
Talazoparibdrug
Likely dose
Talazoparib 1mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02921919
NCT02921919Phase 2Completed
CompareCT.gov

A SINGLE-ARM, OPEN-LABEL, MULTICENTER, EXTENDED TREATMENT, SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB

Pfizer·interventional·Posted Oct 3, 2016·Updated Aug 24, 2022

In Brief

A Phase 2 clinical trial evaluating Talazoparib for Cancer. Completed, enrolled 120 participants across 38 sites in 9 countries.

Detailed Summary

This is a single-arm, open-label, extended treatment, safety study in patients treated with talazoparib in qualifying studies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer
CountriesCanada, France, Germany, Hungary, Moldova, Poland, Russia, United Kingdom, United States
CollaboratorsMedivation, Inc.

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 3, 2016
Enrollment StartNov 8, 2016
Primary CompletionJul 20, 2021
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 9.7 years ago

Interventions

Talazoparibdrug

Maximum starting dose: 1mg/day or last tolerated dose in the originating protocol